XM does not provide services to residents of the United States of America.

Brazil sues Syngenta for alleged environmental damage



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>UPDATE 2-Brazil sues Syngenta for alleged environmental damage</title></head><body>

Adds journalist to byline, Syngenta's statement

By Ricardo Brito and Ana Mano

BRASILIA, July 4 (Reuters) -Brazil's environmental agency IBAMA has sued Syngenta alleging the chemicals company caused "environmental damage" by producing and selling pesticides using much higher concentrations of a carcinogen than allowed under law, according to court documents seen by Reuters.

In the suit filed last week, IBAMA said it was seeking damages to remedy the environmental and human health problems arising from the use of such a toxic product.

IBAMA told a federal judge in Sao Paulo it had found evidence of use of a substance called "bronopol" at levels almost three times above the quantity authorized in the manufacturing of insecticide "Engeo Pleno."

That substance was also illegally added to insecticides "Karate Zeon 250 CS" and "Karate Zeon 50 CS" but is not a part of their formula, according to IBAMA's allegations.

Syngenta said it presented before the court "proof of the non-existence of any type of risk or environmental damage" resulting from the allegations made.

The Switzerland-headquartered firm said health agency ANVISA, the agriculture ministry and IBAMA itself recently approved a new version of "Engeo Pleno" which would be "based on the levels of bronopol found in the formulations mentioned in the suit."

The company did not comment on the other two products, but said it took multiple measures "to eliminate any possibility of failure of the nature detected by IBAMA during an inspection in 2021."

Syngentawould have produced 4.7 million liters of these three insecticides, of which at least 4.4 million were marketed, according to evidence produced by the agency and presented to the court.

IBAMA estimates that the sale of the allegedly adulterated products generated more than 400 million reais ($73 million) for the company.

The agency has also asked the judge to force the company, controlled byChemChina since 2017, to identify, collect and properly dispose of products sold that have not yet been withdrawn from the market.

The courts have not made any decisions yet.

The value of the compensation will be determined during the course of proceedings, according to court documents.

To guarantee payment of damages in case IBAMA wins the case, the agency has asked the court to require the company to set aside 90 million reais.


($1 = 5.4849 reais)



Reporting by Ricardo Brito, writing by Ana Mano
Editing by Alistair Bell, David Gregorio and Deepa Babington

</body></html>

Disclaimer: The XM Group entities provide execution-only service and access to our Online Trading Facility, permitting a person to view and/or use the content available on or via the website, is not intended to change or expand on this, nor does it change or expand on this. Such access and use are always subject to: (i) Terms and Conditions; (ii) Risk Warnings; and (iii) Full Disclaimer. Such content is therefore provided as no more than general information. Particularly, please be aware that the contents of our Online Trading Facility are neither a solicitation, nor an offer to enter any transactions on the financial markets. Trading on any financial market involves a significant level of risk to your capital.

All material published on our Online Trading Facility is intended for educational/informational purposes only, and does not contain – nor should it be considered as containing – financial, investment tax or trading advice and recommendations; or a record of our trading prices; or an offer of, or solicitation for, a transaction in any financial instruments; or unsolicited financial promotions to you.

Any third-party content, as well as content prepared by XM, such as: opinions, news, research, analyses, prices and other information or links to third-party sites contained on this website are provided on an “as-is” basis, as general market commentary, and do not constitute investment advice. To the extent that any content is construed as investment research, you must note and accept that the content was not intended to and has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such, it would be considered as marketing communication under the relevant laws and regulations. Please ensure that you have read and understood our Notification on Non-Independent Investment. Research and Risk Warning concerning the foregoing information, which can be accessed here.

Risk Warning: Your capital is at risk. Leveraged products may not be suitable for everyone. Please consider our Risk Disclosure.